Title: Labetalol, an alpha‐ and beta‐adrenoceptor‐blocking agent: its use in therapeutics. A summary of the symposium.
Abstract: British Journal of Clinical PharmacologyVolume 8, Issue S2 p. 239S-244S Free Access Labetalol, an alpha- and beta-adrenoceptor-blocking agent: its use in therapeutics. A summary of the symposium. BN Prichard, BN PrichardSearch for more papers by this authorDA Richards, DA RichardsSearch for more papers by this author BN Prichard, BN PrichardSearch for more papers by this authorDA Richards, DA RichardsSearch for more papers by this author First published: April 1979 https://doi.org/10.1111/j.1365-2125.1979.tb04788.xCitations: 8AboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL References ANDERSSON, O., BERGLUND, G. & HANSSON, L. (1976). Anti-hypertensive action, time of onset and effects of carbohydrate metabolism of labetalol. Br. J. clin. Pharmac., 3, Suppl., 757– 761. BAHLMANN, J., BROD, J., HUBRICK, W., CACHOVAN, M. & PRETSCHNER, P. (1979). The effect of an α- and β-blocking agent (labetalol) on haemodynamics in hypertension. Br. J. clin. Pharmac., 8, Suppl., 2, 113S– 117S. BAILEY, R. R. (1979). Labetalol in the treatment of patients with hypertension and renal function impairment. Br. J. clin. Pharmac., 8, Suppl., 2, 135S– 140S. BALASUBRAMANIAN, V., MANN, S., MILLAR-CRAIG, M.W. & RAFTERY, E.B. (1979a). Effect of labetalol in hypertension during exercise and postural changes. Br. J. clin. Pharmac., 8, Suppl., 2, 95S– 100S. BALASUBRAMANIAN, V., MANN, S., RAFTERY, E.B., MILLAR-CRAIG, M.W. & ALTMAN, D. (1979b). The effect of labetalol on continuous ambulatory blood pressure. Br. J. clin. Pharmac., 8, suppl. 2, 119S– 123S. BEILIN, L.S. & JUEL-JENSEN, B.E. (1972). α- and β-adrenergic blockade in hypertension. Lancet, 1, 979– 982. BESTERMAN, E.M.M. & SPENCER, M. (1979). Open evaluation of labetalol in the treatment of angina pectoris occurring in hypertensive patients. Br. J. clin. Pharmac., 8, suppl. 2, 205S– 209S. BOAKES, A.J. & PRICHARD, B.N.C. (1973). The effect of AH5158, pindolol, propranolol and d-propranolol on acute exercise tolerance in angina pectoris. Br. J. Pharmac., 47, 673P. BOLLI, P., WAAL-MANNING, H.J., WOOD, A.J. & SIMPSON, F.O. (1976). Experience with labetalol in hypertension. Br. J. clin. Pharmac., 3, Suppl., 765– 771. CHRISTIENSEN, N.J., TRAP-JENSEN, J., SVENDSEN, T.L., RASMUSSEN, S. & NEILSEN, P.E. (1978). Effect of labetalol on plasma noradrenaline and adrenaline in hypertensive man. Eur. J. clin. Pharmac., 14, 227– 230. COPE, D.H.P. (1979). Use of labetalol during halothane anaesthesia. Br. J. clin. Pharmac., 8, suppl. 2, 223S– 227S. CUMMING, A.A.M., BROWN, J.J., FRASER, R., LEVER, A.F., MORTON, J.J., RICHARDS, D.A. & ROBERTSON, J.I.S. (1979a). Blood pressure reduction by incremental infusion of labetalol in patients with severe hypertension. Br. J. clin. Pharmac. (in press). CUMMING, A.M.M., BROWN, J.J., LEVER, A.F., MACKAY, A. & ROBERTSON, J.I.S. (1979b). Treatment of severe hypertension by repeated bolus injections of labetalol. Br. J. clin. Pharmac., 8, suppl. 2, 199S– 204S. DARGIE, H.J., DOLLERY, C.T. & DANIEL, J. (1976). Labetalol in resistent hypertension. Br. J. clin. Pharmac., 3, Suppl., 751– 755. DOLLERY, C.T. (1976). Symposium on labetalol. Closing remarks. Current status of labetalol. Br. J. clin. Pharmac., 3, Suppl., 823– 824. DREW, G.M. (1978). Pharmacological characteristics of the presynaptic α-adrenoceptor regulating cholinergic activity in the guinea-pig ileum. Br. J. Pharmac., 64, 293– 300. EDWARDS, R.C. & RAFTERY, E.B. (1976). Haemodynamic effects of long-term oral labetalol. Br. J. clin. Pharmac., 3, Suppl., 733– 736. GHOSE, R.R. (1979). Acute management of severe hypertension with oral labetalol. Br. J. clin. Pharmac., 8, suppl. 2, 189S– 193S. HAMILTON, C.A., JONES, D.H., DARGIE, H.J. & REID, J.L. (1978). Does labetalol increase excretion of urinary catecholamines Br. med. J., 2, 800. HANSSON, L. & HÄNEL, B. (1976). Labetalol, a new α- and β-adrenoceptor blocking agent in hypertension. Br. J. clin. Pharmac., 3, Suppl., 763– 765. HARRIS, D.M. & RICHARDS, D.A. (1978). Beta blockers in treatment of hypertension. Br. med. J., 2, 894. KANE, J., GREGG, I. & RICHARDS, D.A. (1976). A double-blind trial of labetalol. Br. J. clin. Pharmac., 3, Suppl., 737– 774. KANE, J., GREGG, I. & STEPHENS, M.D.B. (1979). A long term study of labetalol in general practice. Br. J. clin. Pharmac., 8, suppl. 2, 167S– 170S. KAUFMAN, L. (1979). Use of labetalol during hypotensive anaesthesia and in the management of phaeochromocytoma. Br. J. clin. Pharmac., 8, suppl. 2, 229S– 232S. KOCH, G. (1976). Combined α- and β-adrenoceptor blockade with oral labetalol in hypertensive patients with reference to haemodynamic effects at rest and during exercise. Br. J. clin. Pharmac., 3, Suppl., 729– 732. KOCH, G. (1979). Cardiovascular dynamics after acute and long-term alpha and beta adrenoceptor blockade at rest, supine and standing and during exercise. Br. J. clin. Pharmac., 8, suppl. 2, 101S– 105S. KOLLOCH, R., MIANO, L. & de QUATTRO, V. (1979). Labetalol and urinary catecholamines. Br. med. J., 1, 268– 269. LAMMING, G.D. & SYMONDS, E.M. (1979). Use of labetalol and methyldopa in pregnancy-induced hypertension. Br. J. clin. Pharmac., 8, suppl. 2, 217S– 222S. LUND-JOHANSEN, P. (1979). Comparative haemodynamic effects of labetalol, timolol, prazosin and the combination of tolamolol and prazosin. Br. J. clin. Pharmac., 8, suppl. 2, 107S– 111S. MARX, P.C. & REID, D.S. (1979). Labetalol infusion in acute myocardial infarction with systemic hypertension. Br. J. clin. Pharmac., 8, suppl. 2, 233S– 238S. McNEIL, JJ., ANDERSON, A.E., LOUIS, W.J. & MORGAN, D.J. (1979a). The pharmacokinetic and pharmacodynamic studies of labetalol in hypertensive subjects. Br. J. clin. Pharmac., 8, suppl. 2, 157S– 161S. McNEIL, J.J. & LOUIS, W.J. (1979b). A double-blind cross-over comparison of pindolol, metoprolol, atenolol and labetalol in mild to moderate hypertension. Br. J. clin. Pharmac., 8, suppl. 2, 163S– 166S. MEHTA, J. & COHN, J.N. (1977). Hemodynamic effects of labetalol, an alpha and beta adrenergic blocking agent, in hypertensive subjects. Circulation, 55, 370– 375. MICHAEL, C.A. (1979). Use of labetalol in the treatment of severe hypertension during pregnancy. Br. J. clin. Pharmac., 8, suppl. 2, 211S– 215S. NEW ZEALAND HYPERTENSION STUDY GROUP (1979). A multicentre open tril of labetalol in New Zealand. Br. J. clin. Pharmac., 8, suppl. 2, 179S– 182S. NICHOLAS, T.E., LUGG, M.A. & JOHNSON, R.G. (1978). Maternal administration of salbutamol and labetalol increases the amount of alveolar surfactant in lung of the day 27 foetal rabbit. Proc. Austr. Physiol. Pharmac. Soc., 9 (2, 146. PEARSON, R.M., GRIFFITH, D.N.W., WOOLLARD, M., JAMES, I.M. & HAVARD, G.W.H. (1979). Comparison of effects on cerebral blood flow of rapid reduction in systemic arterial pressure by diazoxide and labetalol in hypertensive patients: Preliminary findings. Br. J. clin. Pharmac., 8, suppl. 2, 195S– 198S. PRICHARD, B.N.C. (1978). β-adrenergic receptor blockade in hypertension, past, present and future. Br. J. clin. Pharmac., 5, 379– 399. PRICHARD, B.N.C. & BOAKES, A.J. (1976). Labetalol in long-term treatment of hypertension. Br. J. clin. Pharmac., 3, Suppl., 743– 750. PRICHARD, B.N.C., BOAKES, A.J. & HERNANDEZ, R. (1979). Long-term treatment of hypertension with labetalol. Br. J. clin. Pharmac., 8, suppl. 2, 171S– 177S. PRICHARD, B.N.C., JOHNSTON, A.W., HILL, I.D. & ROSENHEIM, M.L. (1968). Bethanidine, guanethidine and methyldopa in the treatment of hypertension; a within-patient comparison. Br. med. J., 1, 135– 144. PRICHARD, B.N.C., THOMPSON, F.O., BOAKES, A.J. & JOEKES, A.M. (1975). Some haemodynamic effects of compound AH 5158 compared with propranolol, propranolol plus hydrallazine, and diazoxide: the use of AH 5158 in the treatment of hypertension. Clin. Sci. molec. Med., 48, 97s. PRICHARD, B.N.C. & TUCKMAN, J. (1977). Management and mechanisms of drug treatment of hypertension. In Hypertension Ed. J. Genest, E. Kiow and O. Kuchel pp. 1085– 1117. New York: McGraw-Hill. PUGSLEY, D.J., ARMSTRONG, B.K., NASSIM, M.A. & BEILIN, L.J. (1976). Controlled comparison of labetalol and propranolol in the management of severe hypertension. Br. J. clin. Pharmac., 3, Suppl., 777– 782. RICHARDS, D.A., HARRIS, D.M. & MARTIN, L.E. (1979a). Labetalol and urinary catecholamines. Br. med. J., 1, 685. RICHARDS, D.A. & PRICHARD, B.N.C. (1979). Clinical pharmacology of labetalol. Br. J. clin. Pharmac., 8, suppl. 2, 89S– 93S. RICHARDS, D.A., PRICHARD, B.N.C. & HERNANDEZ, R. (1979b). Circulatory effects of noradrenaline and adrenaline before and after labetalol. Br. J. clin. Pharmac., 7, 371– 378. RICHARDS, D.A., PRICHARD, B.N.C. & HERNANDEZ, R. (1979c). Sympathomimetic amine infusion after β-adrenoceptor and parasympathetic blockade. Br. J. clin. Pharmac., 7, 429P. SANDERS, G.L., DAVIES, D.M., GALES, G.M., RAO, J.G., RAWLINS, M.D. & ROUTLEDGE, P.A. (1979a). A comparative study of methyldopa and labetalol in the treatment of hypertension. Br. J. clin. Pharmac., 8, suppl. 2, 149S– 151S. SANDERS, G.L., MURRAY, A. & RAWLINS, M.D. (1979b). Interdose control of β-blockade and arterial blood pressure during chronic oral labetalol treatment. Br. J. clin. Pharmac., 8, suppl. 2, 125S– 127S. SANDERS, G.L., ROUTLEDGE, P.A., WARD, A., DAVIES, D.M. & RAWLINS, M.D. (1979c). Mean steady-state plasma concentrations of labetalol in patients undergoing antihypertensive therapy. Br. J. clin. Pharmac., 8, suppl. 2, 153S– 155S. SCOTT, D.B., BUCKLEY, F.P., LITTLEWOOD, D.G., MACRAE, W.R. ARTHUR, G.R. & DRUMMOND, G.B. (1978). Circulatory effects of labetalol during halothane anaesthesia. Anaesthesia, 33, 145– 156. THOMPSON, F.D., JOEKES, A.M. & HUSSEIN, M.M. (1979). Monotherapy with labetalol for hypertensive patients with normal and impaired renal function. Br. J. clin. Pharmac., 8, suppl. 2, 129S– 133S. WILLIAMS, L.C., MURPHY, M.J. & PARSONS, V. (1979). Labetalol in severe and resistant hypertension. Br. J. clin. Pharmac., 8, suppl. 2, 143S– 147S. WILSON, J.D., BULLOCK, J.Y., SUTHERLAND, D.C., MAIN, C. & O'BRIEN, K.P. (1978). Antinuclear antibodies in patients receiving non-practolol beta-blockers. Br. med. J., 1, 14– 16. Citing Literature Volume8, IssueS2April 1979Pages 239S-244S ReferencesRelatedInformation